Continuum Clinical, a BC Worldwide company, Acquired by Spectrum Science, a Portfolio Company of Knox Lane, to Bolster Patient Engagement Capabilities


Continuum Clinical (“Continuum”), a BC Worldwide company, was acquired by Spectrum Science (“Spectrum”), a portfolio company of Knox Lane, to bolster their patient engagement capabilities.


The rising number of clinical trials is driving demand for patient recruitment and retention services. These trials are crucial for studying new medical procedures and medications, evaluating their impact on patient health outcomes. Patient recruitment and engagement services play a vital role by identifying and enrolling eligible participants. The global market for these services is expected to grow to $4.67 billion in 2027 (from $3.78 billion in 2023).

Established in 1993, Continuum Clinical has been a leading provider of tech-enabled patient recruitment solutions, having supported over 280 clinical trials across 52 countries, spanning more than 200 unique indications. Renowned for their success in oncology trials and enduring partnerships with global pharmaceutical and biotech companies, including 11 of the top 20 global Sponsors, Continuum has earned a white-glove reputation as a trusted provider of patient engagement solutions. This stellar track record made Continuum an ideal acquisition for Knox Lane-backed Spectrum Science to enhance its patient engagement capabilities.

Crosstree’s Role

Crosstree’s expertise in the pharma services sector, particularly within patient engagement, coupled with a thorough comprehension of Continuum’s distinctive value proposition, enabled the firm to guide Continuum in recognizing Spectrum as the optimal transaction partner through:

  • Presenting the Continuum’s unique value proposition to help them achieve a record number of offers
  • Positioning Continuum to maximize value
  • Partnering with Blue Chip Worldwide to successfully carve out Continuum’s operations


Pharma Services


Merger and Acquisition

Deal Tags

Clinical Trials
Pharma Development
Patient and Site Engagement